Mirum Pharmaceuticals, Inc.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. carries a market capitalization of 6.63B, placing it among publicly traded companies globally. Its enterprise value stands at 6.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mirum Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. has 64.75M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.64, and the price-to-book ratio stands at -726.88.

These figures are as of June 30, 2026. The EV/Sales ratio of 12.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.92B versus a market cap of 6.63B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -7,320.56, indicating conservative leverage, while an interest coverage ratio of -60.13 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -97.15, reflecting losses generated across the asset base. The company generates approximately 1.50M in revenue per employee across its workforce of 359.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.64 indicates how many times Mirum Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. recorded 2.34M in income tax expense. The company reported a pretax loss of -750.60M and -752.94M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Mirum Pharmaceuticals, Inc.'s stock has gained approximately 23.40% over the past 52 weeks. The 50-day moving average sits at 80.16, while the 200-day moving average is 85.60.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. generated 540.99M in revenue and converted that into -752.94M in net income, yielding earnings per share of -13.03. EBITDA reached -707.26M, while operating income came in at -79.85M.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. holds 383.64M in cash and equivalents against 667.81M in total debt, resulting in a net debt position of 367.06M. Total book value stands at -9.12M, with working capital of 361.96M providing operational flexibility.

Mirum Pharmaceuticals, Inc. produced -198.93M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.93M in capital expenditures, free cash flow totaled -230.85M - equivalent to -4.11 per share.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. posted a gross margin of 81.72, reflecting its pricing power and cost economics. The operating margin of -14.76 and net profit margin of -139.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.90: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.69, meaning Mirum Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. has an Altman Z-Score of 2.65, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.